Proton pump inhibitors (PPIs) can alleviate upper gastrointestinal injury but paradoxically exacerbate aspirin (ASA)-induced small intestine injury. In this study, our goal was to simulate this exa...
28 January 2021 in Journal of Gastroenterology and Hepatology
This retrospective cohort study compared the number of newly diagnosed patients, stage at diagnosis, and detection process of gastrointestinal cancers based on hospital-based cancer registry data at two tertiary Japanese hospitals. The pre-COVID-19 period was from January 2017 to February 2020, with phase 1 (midst of COVID-19 pandemic) from March to December 2020 and phase 2 (the transition period to the “new normal”) from January to December 2021. Each month, the number of patients diagnosed with esophageal, gastric, colorectal, pancreatic, liver, and biliary tract cancers were aggregated, classified by stage and detection process, and compared, including a total of 6453 patients. The number of colorectal Stage 0-II patients decreased significantly in phase 1 and increased in phase 2. The total number of colorectal cancer patients returned to pre-COVID-19 levels (mean monthly patients [SD]: 41.61 [6.81] vs. 36.00 [6.72] vs. 46.00 [11.32]). The number of patients with gastric cancer Stage I significantly decreased in phase 2 following phase 1. The number of gastric cancer patients decreased significantly from pre-COVID-19 levels (30.63 [6.62] vs. 22.40 [5.85] vs. 24.50 [4.15]). During phase 2, the number of patients diagnosed after screening with colorectal cancer increased significantly, whereas that with gastric cancer remained considerably lower. The number of Stage III colorectal and gastric cancer patients increased significantly from the pre-COVID-19 levels. Thus, gastric cancer may not be optimally screened during phases 1 and 2. There was a significant increase in patients with Stage III colorectal and gastric cancers from the pre-COVID-19 period; hence, the stage at diagnosis may have progressed.
Background and study aims Multiple large colorectal lesions are sometimes diagnosed during colonoscopy. However, there have been no investigations of the feasibility of simultaneous endoscopic submucosal dissection (ESD) for multiple lesions. This study aims to reveal the strategy of simultaneous ESD for multiple large colorectal lesions. Patients and methods 246 patients who underwent ESD for 274 colorectal lesions were retrospectively evaluated in this study. Fifty-one large colorectal lesions among 23 patients were treated by ESD simultaneously (simultaneous group), and 223 patients were treated with ESD for a single lesion (single group). Results En-bloc resection and curative resection rates did not differ. Compared with the single group, each procedure time was faster (31.8 ± 23.6 min vs. 45.8 ± 44.8, P = 0.002), but total procedure time was significantly longer in the simultaneous group (70.6 ± 33.4 vs. 45.8 ± 44.8 min, P = 0.01). Rates of adverse events including bleeding and perforation were not higher in the simultaneous group but the mean blood pressure, incidence of bradycardia and the amount of sedative drug used during ESD were significantly higher in the simultaneous group. Multiple logistic regression analysis identified non-experienced physician, lesion size ≥ 40 mm and submucosal fibrosis as an independent risk factor for procedure duration (≥ 90 min) (Odds ratio 11.852, 18.280, and 3.672; P < 0.05, respectively). Conclusions Simultaneous ESD for multiple synchronous colorectal lesions is safe and feasible compared with single ESD and can reduce the burden to patients, length of hospital stay and medical expense. These results need to be elucidated by further studies.
Endoscopic submucosal dissection (ESD) for gastrointestinal lesions enables en bloc resection with tumor-free margins and is not limited by the lesion size or location. However, en bloc removal of colorectal lesions with severe fibrosis is difficult and requires a longer time [1] [2]. We report the successful resection of an early rectal tumor by colorectal ESD with a new method: double-tunnel ESD. A 68-year-old man was referred to our hospital for treatment of a large sub-protruded rectal lesion measuring about 60 mm in diameter ([Fig. 1 a]). He underwent ESD, which was performed using a dual knife (KD-650U; Olympus, Tokyo, Japan), with the patient under deep sedation. Our plan to achieve en bloc resection of this large sub-protruded lesion, a type of lesion that often has severe fibrosis or displays the muscle-retracting sign during ESD [3], was first to open two different tunnels on each side of the severe fibrosis from the anal side of the lesion ([Fig. 1 b]). This technique allows good traction to be maintained and an appropriate dissection line to be identified, even in the presence of severe fibrosis. Subsequently, the two tunnels were connected ([Video 1]). Finally, mucosal and submucosal dissections were performed from both sides to open the lesion from the lower side against gravity ([Fig. 1 c]). After this, the lesion was completely resected en bloc without any complications ([Fig. 1 d]). The tumor was 59 × 50 mm in size; histological examination revealed a submucosally invasive carcinoma, with all the margins being tumor-free ([Fig. 2]). Video 1 Colorectal endoscopic submucosal dissection with the double-tunnel method is used to resect a lesion with severe fibrosis efficiently and safely because good traction is maintained and an appropriate dissection line can be identified. ESD using the double-tunnel method can achieve reliably efficient and safe resection of colorectal lesions with severe fibrosis or displaying the muscle-retracting sign. Endoscopy_UCTN_Code_TTT_1AQ_2AD
Objectives Gastrointestinal endoscopy (GIE) is useful for the early detection and treatment of many diseases; however, GIE is considered a high‐risk procedure in the coronavirus disease 2019 (COVID‐19) pandemic era. This study aimed to explore the rate of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity in saliva and gastrointestinal fluids to which endoscopy medical staff are exposed. Methods The study was a single‐center cross‐sectional study. From June 1 to July 31, 2020, all patients who underwent GIE at Yokohama City University Hospital were registered. All patients provided 3 ml of saliva. For upper GIE, 10 ml of gastric fluid was collected through the endoscope. For lower GIE, 10 ml of intestinal fluid was collected through the endoscope. The primary outcome was the positive rate of SARS‐CoV‐2 in saliva and gastrointestinal fluids. We also analyzed serum‐specific antibodies for SARS‐CoV‐2 and patients’ background information. Results A total of 783 samples (560 upper GIE and 223 lower GIE samples) were analyzed. Polymerase chain reaction (PCR) on saliva samples did not show any positive results in either upper or lower GIE samples. However, 2.0% (16/783) of gastrointestinal fluid samples tested positive for SARS‐CoV‐2. No significant differences in age, sex, purpose of endoscopy, medication, or rate of antibody test positivity were found between PCR positive and PCR negative cases. Conclusions Asymptomatic patients, even those with no detectable virus in their saliva, had SARS‐CoV‐2 in their gastrointestinal tract. Endoscopy medical staff should be aware of infection when performing procedures. The study was registered as UMIN000040587.